

3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

ProductInformation

Anti-Flotillin 2 (C-terminal)

produced in rabbit, affinity isolated antibody

Catalog Number F1680

Product Description

Anti-Flotillin 2 is produced in rabbit using as immunogen a synthetic peptide corresponding to amino acid residues 415-428 of human flotillin 2 with an N-terminal added cysteine, conjugated to KLH (GeneID: 2319). The corresponding sequence differs by two amino acids in rat and mouse. The antibody is affinity-purified using the immunizing peptide immobilized on agarose.

Anti-Flotillin 2 (C-terminal) recognizes human flotillin 2. Applications include immunoblotting (~ 48 kDa) and immunofluorescence. Detection of the flotillin 2 band by immunoblotting is specifically inhibited with the immunizing peptide.

Flotillins are lipid raft-associated proteins involved in various cellular processes such as endocytosis. phagocytosis, neuronal regeneration and insulin signaling. 1, 2 Lipid raft microdomains are glycosphingolipid- and cholesterol-rich membrane organized, dynamic structures connected to the cytoskeleton. Lipid raft domains are insoluble in non-ionic detergents, have a low buoyant density and contain proteins such as Src family kinases, glycosylphosphatidylinositol (GPI)-linked proteins, caveolins, sphingolipids, and cholesterol. Lipid rafts have a central role in cellular organization, membrane trafficking and signaling events.^{3, 4} The flotillin protein family consists of two proteins, flotillin 1 and 2, also named reggie-2 and -1, respectively. Flotillins belong to a larger family of integral membrane proteins that contain an evolutionarily conserved domain called the prohibitin homology (PHB) domain or SPFH domain (stomatin/prohibitin/flotillin/HflK/C domain). It has been suggested that the PHB domain constitutes a lipid recognition motif which can target proteins to the plasma membrane.^{2, 4} The association of flotillin 1 to the plasma membrane depends on palmitoylation in a conserved Cys³⁴ residue, whereas the association of flotillin 2 depends on both myristolation and palmitoylation.2,5

The flotillin proteins are conserved and ubiquitously expressed. Flotillin 1 and 2 show a complementary tissue distribution. Flotillin 1 is mainly expressed in striated muscle tissues, adipose tissue, and lung. Flotillin 2 is more widely distributed, but is absent in skeletal muscle.⁶

Flotillin 2 over expression is associated with melanoma progression and transformation of SB2 melanoma cells to a highly metastatic line. It is also associated with expression of the thrombin receptor, PAR-1, that is implicated in cell growth and metastasis. Flotillin 2 may be used as a marker protein for lipid raft microdomains.

Reagent

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide as preservative.

Antibody concentration: ~1 mg/mL

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Product Profile

Immunoblotting: a working concentration of 0.5-1 μ g/mL is recommended using whole extract of human HeLa cells

Indirect immunofluorescence: a working concentration of 5-10 μ g/mL is recommended by staining human HEK-293T cells.

Note: In order to obtain the best results using various techniques and preparations, we recommend determining the optimal working dilutions by titration.

References

- Bickel, P.E., et al., J. Biol. Chem., 272, 13793-13802 (1997).
- 2. Neumann-Giesen, C., et al., *Biochem. J.*, **378**, 509-518 (2004).
- 3. Salzer, U., and Prohaska, R., *Blood*, **97**, 1141-1143 (2001).

- 4. Liu, J., et al., *J. Biol. Chem.*, **280**, 16125-16134 (2005).
- 5. Morrow, I.C., et al., *J. Biol. Chem.*, **277**, 48834-48841 (2002).
- 6. Volonte, D., et al., *J. Biol. Chem.*, **274**, 12702-12709 (1999).
- 7. Hazarika, P., et al, Cancer Res., **64**, 7361-7369 (2004).

ST, AH, KAA, PHC 12/06-1